These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 19616557

  • 21. Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency.
    Leung MY, Cohen FS.
    Biophys J; 2011 Apr 20; 100(8):1960-8. PubMed ID: 21504732
    [Abstract] [Full Text] [Related]

  • 22. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.
    Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, Ratcliffe D, Workman J, Joall A, Myers R, Smit E, Cane PA, Greenberg ML, Pillay D.
    Antimicrob Agents Chemother; 2005 Mar 20; 49(3):1113-9. PubMed ID: 15728911
    [Abstract] [Full Text] [Related]

  • 23. Structural and Thermodynamic Analysis of HIV-1 Fusion Inhibition Using Small gp41 Mimetic Proteins.
    Jurado S, Cano-Muñoz M, Morel B, Standoli S, Santarossa E, Moog C, Schmidt S, Laumond G, Cámara-Artigas A, Conejero-Lara F.
    J Mol Biol; 2019 Aug 09; 431(17):3091-3106. PubMed ID: 31255705
    [Abstract] [Full Text] [Related]

  • 24. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
    Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.
    Cell; 2007 Apr 20; 129(2):263-75. PubMed ID: 17448989
    [Abstract] [Full Text] [Related]

  • 25. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.
    Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.
    J Biol Chem; 2009 Feb 20; 284(8):4914-20. PubMed ID: 19073606
    [Abstract] [Full Text] [Related]

  • 26. Addition of artificial salt bridge by Ile646Lys mutation in gp41 coiled-coil domain regulates 6-helical bundle formation.
    Zhao L, Hu ZW, Tong P, Chen YX, Zhao YF, Li YM.
    Bioorg Med Chem Lett; 2013 May 01; 23(9):2727-32. PubMed ID: 23522564
    [Abstract] [Full Text] [Related]

  • 27. Stronger anti-HIV-1 activity of C-peptide derived from HIV-1 89.6 gp41 C-terminal heptad repeated sequence.
    Seo JK, Kim HK, Lee TY, Hahm KS, Kim KL, Lee MK.
    Peptides; 2005 Nov 01; 26(11):2175-81. PubMed ID: 15876473
    [Abstract] [Full Text] [Related]

  • 28. Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.
    Gustchina E, Louis JM, Bewley CA, Clore GM.
    J Mol Biol; 2006 Dec 01; 364(3):283-9. PubMed ID: 17010381
    [Abstract] [Full Text] [Related]

  • 29. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
    Julien JP, Bryson S, Nieva JL, Pai EF.
    J Mol Biol; 2008 Dec 12; 384(2):377-92. PubMed ID: 18824005
    [Abstract] [Full Text] [Related]

  • 30. Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket.
    Zhang X, Zhu Y, Hu H, Zhang S, Wang P, Chong H, He J, Wang X, He Y.
    Front Cell Infect Microbiol; 2018 Dec 12; 8():51. PubMed ID: 29535974
    [Abstract] [Full Text] [Related]

  • 31. An alternative conformation of the gp41 heptad repeat 1 region coiled coil exists in the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor.
    Mische CC, Yuan W, Strack B, Craig S, Farzan M, Sodroski J.
    Virology; 2005 Jul 20; 338(1):133-43. PubMed ID: 15950253
    [Abstract] [Full Text] [Related]

  • 32. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
    Jiang S, Debnath AK.
    Biochem Biophys Res Commun; 2000 Mar 24; 269(3):641-6. PubMed ID: 10720469
    [Abstract] [Full Text] [Related]

  • 33. The role of the N-terminal heptad repeat of HIV-1 in the actual lipid mixing step as revealed by its substitution with distant coiled coils.
    Wexler-Cohen Y, Sackett K, Shai Y.
    Biochemistry; 2005 Apr 19; 44(15):5853-61. PubMed ID: 15823044
    [Abstract] [Full Text] [Related]

  • 34. The crystal structure of HIV CRF07 B'/C gp41 reveals a hyper-mutant site in the middle of HR2 heptad repeat.
    Du J, Xue H, Ma J, Liu F, Zhou J, Shao Y, Qiao W, Liu X.
    Virology; 2013 Nov 19; 446(1-2):86-94. PubMed ID: 24074570
    [Abstract] [Full Text] [Related]

  • 35. Identification of the HIV-1 gp41 core-binding motif--HXXNPF.
    Huang JH, Liu ZQ, Liu S, Jiang S, Chen YH.
    FEBS Lett; 2006 Sep 04; 580(20):4807-14. PubMed ID: 16904109
    [Abstract] [Full Text] [Related]

  • 36. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides.
    Shu W, Liu J, Ji H, Radigen L, Jiang S, Lu M.
    Biochemistry; 2000 Feb 22; 39(7):1634-42. PubMed ID: 10677212
    [Abstract] [Full Text] [Related]

  • 37. Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor.
    Kinomoto M, Yokoyama M, Sato H, Kojima A, Kurata T, Ikuta K, Sata T, Tokunaga K.
    J Virol; 2005 May 22; 79(10):5996-6004. PubMed ID: 15857986
    [Abstract] [Full Text] [Related]

  • 38. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
    Chong H, Yao X, Qiu Z, Sun J, Zhang M, Waltersperger S, Wang M, Liu SL, Cui S, He Y.
    FASEB J; 2013 Mar 22; 27(3):1203-13. PubMed ID: 23233535
    [Abstract] [Full Text] [Related]

  • 39. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
    Chong H, Qiu Z, Su Y, Yang L, He Y.
    AIDS; 2015 Jan 02; 29(1):13-21. PubMed ID: 25562490
    [Abstract] [Full Text] [Related]

  • 40. Structural analysis and assembly of the HIV-1 Gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at-interface sequence.
    Lorizate M, de la Arada I, Huarte N, Sánchez-Martínez S, de la Torre BG, Andreu D, Arrondo JL, Nieva JL.
    Biochemistry; 2006 Dec 05; 45(48):14337-46. PubMed ID: 17128972
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.